Standard Methotrexate Dosing by Age Group
Methotrexate dosing varies by indication (e.g., rheumatoid arthritis, psoriasis, cancer) and route (oral, subcutaneous, IV), with adjustments primarily for renal function rather than age alone. Guidelines from the American College of Rheumatology (ACR) and FDA labeling emphasize monitoring creatinine clearance (CrCl) in older adults, as age-related kidney decline increases toxicity risk.[1][2]
- Adults (18-64 years): For rheumatoid arthritis, typical low-dose is 7.5-25 mg once weekly (oral or subcutaneous). No routine age-specific adjustment if CrCl >60 mL/min.[1]
- Elderly (≥65 years): Use lowest effective dose (e.g., start at 7.5 mg/week for RA). Reduce by 25-50% if CrCl 30-60 mL/min; avoid if <30 mL/min due to myelosuppression and hepatotoxicity risks. Frequent monitoring (CBC, liver enzymes, CrCl every 1-3 months).[1][3]
Pediatric dosing exists for juvenile idiopathic arthritis or cancer but scales by body surface area (BSA), not chronological age alone (e.g., 15 mg/m²/week max for JIA).[4]
Why Renal Function Drives Adjustments Over Age
Age correlates with declining glomerular filtration rate (GFR); patients over 70 often have CrCl <60 mL/min, raising methotrexate levels and risks like pancytopenia. Cockcroft-Gault formula estimates CrCl using age, weight, and serum creatinine—key for dosing decisions.[2][5]
Adjustments for Low-Dose vs. High-Dose Regimens
- Low-dose (non-oncologic, e.g., RA/psoriasis): Weekly total ≤30 mg; split doses if >20 mg to cut GI upset. Elderly: Halve if CrCl <50 mL/min.[1]
- High-dose (oncology, e.g., leukemia): 1-12 g/m² IV with leucovorin rescue. Elderly: Reduce by 20-30% if CrCl 30-60 mL/min; contraindicated if <30 mL/min. Hydration and urine alkalinization required.[3][6]
Common Risks and Monitoring in Older Patients
Elderly patients face 2-3x higher toxicity rates (e.g., 15-20% severe events vs. 5-10% in younger adults). Weekly blood tests mandatory; hold if platelets <100,000/μL or CrCl drops.[1][7] Drug interactions (e.g., NSAIDs, PPIs) amplify risks.
Dosing in Pediatrics vs. Geriatrics
| Age Group | Example Indication | Typical Dose | Key Adjustment Trigger |
|-----------|-------------------|--------------|-----------------------|
| Pediatrics (<18 years) | JIA | 10-15 mg/m²/week (max 25 mg) | BSA, not age; monitor growth[4] |
| Adults | RA | 7.5-25 mg/week | CrCl >60 mL/min[1] |
| Elderly (≥65) | RA | Start 7.5 mg/week; reduce if CrCl <60 | Renal decline, frailty[3] |
When to Consult Specialists
Rheumatologists or oncologists tailor doses; no universal "age-only" formula exists. Use tools like methotrexate toxicity calculators for CrCl-based tweaks.[5]
Sources
[1]: ACR RA Guidelines (2021)
[2]: FDA Methotrexate Label
[3]: UpToDate: Methotrexate in Elderly
[4]: AAP Pediatric Dosing
[5]: Cockcroft-Gault Calculator
[6]: NCCN Cancer Guidelines
[7]: NEJM Methotrexate Toxicity Review